Biogen (BIIB)
(Delayed Data from NSDQ)
$225.43 USD
-6.56 (-2.83%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $225.96 +0.53 (0.24%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 81 - 100 ( 804 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Implications of Full Approval of Leqembi on Second Generation Anti-Amyloid Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Leqembi Full Approval Arrives (as anticipated) -- On To The Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Leqembi AdCom Defines Clinical Meaningfulness for AD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Small But Mighty AdCom Votes To Grant Full Approval For Leqembi
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Leqembi''s Approval Quest: An Encore of Aduhelm Drama Seems Unlikely At AdCom
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
CMS Issues Notice On Alzheimer''s Drug Coverage - Granted With Full FDA Approval
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
History Doesn''t Repeat Itself, But It Often Rhymes; Thoughts On BIIB''s Strategy
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
BIIB080 Might be Next for an Accelerated Approval; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
1Q23 First Take: About As Expected -- Starting To See Pipeline Prioritization
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Getting Fit Doesn''t Happen Overnight -- Thoughts on 1Q23 Update
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Commercial Biotech Preview: Let''s Get It Started
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 4/7/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 41123
Provider: Stock Traders Daily
Analyst: Research Department